

Exploring anticancer properties of Moringa and its derived by-products against colon cancer in humans and animals

Hasnain Haider ¹, Iqra Kousar ², Maham Parvaiz ³, Huma Riffat ¹, Muhammad Ahmar Shahbaz ¹, Nibras Hussain ⁴, Neelam Pari ⁵, Oun Deli Khudhair ⁶, Muhammad Azrul Zabidi ⁶, Tehreem Shehzad ^{*1}

¹ Department of Zoology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan

² Graduate Institute of Biomedical Sciences and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan

³ Institute of Molecular Biology & Biotechnology, The University of Lahore, Pakistan

⁴ Department of Global and Environmental Health, New York University School of Global Public Health, New York, USA

⁵ Department of Biotechnology, COMSATS University Islamabad, Abbotabad Campus, Pakistan

⁶ Advanced Medical and Dental Institute, Universiti Sains Malaysia

Article info

Received: 20 June 2025

Received in revised form: 09 August 2025

Accepted: 11 August 2025

Published online: 02 October 2025

Keywords

Moringa
Cell cycle arrest
Oxidative stress
Apoptosis
Nanoparticles
Phytochemicals

* Corresponding author:

Tehreem Shehzad

Email: shehzadtehreem1122@gmail.com

Reviewed by:

Consent to publish the name of first reviewer could not be obtained

Shaista Shafiq

Department of Biochemistry and
Biotechnology, The university of Faisalabad,
Pakistan

Abstract

Colon cancer continues to be the main cause of neoplasm-related morbidity and mortality in humans and animals worldwide, necessitating the exploration of new, efficient, and less toxic medicinal approaches. Depending on the adverse effects, including genetic toxicity, myelosuppression, hypertension, neurotoxicity, gastrointestinal toxicity, impaired chemosensitivity, nephrotoxicity, cardiovascular issues, neutropenia, etc., conventional therapies such as chemotherapy and radiotherapy need to be replaced by better therapeutic alternatives. This review aims to explore the potential therapeutic benefits of *Moringa oleifera* and its nano-formulations against colon cancer. Moringa, a medicinal plant rich in active chemicals, and its biosynthesized nanoparticles have the potential to hinder the growth and proliferation of colon cancerous cells through arresting cell division at different phases, promoting cell death by disrupting mitochondrial membrane potential, inducing oxidative stress leading to DNA damage, and hindering cancer-causing signalling pathways like PI3K/Akt, NF- κ B, and ERK. Moreover, the review highlights that future research should evaluate the safety and efficacy of Moringa and its NPs through clinical trials, observing the effect of Moringa and its NPs on different molecular pathways, enhancing the production of NPs, assessing the use of combination therapy, and examining whether Moringa plays a role in treating other cancers. Although the findings of laboratory and animal studies are encouraging, further *in vivo* and clinical evaluation is needed to validate these findings in practical applications. In conclusion, Moringa and its NPs demonstrate promising potential for translation into therapeutic agents for CC.

This is an open access article under the CC Attribution license (<http://creativecommons.org/licenses/by/4.0/>)

1. Introduction

Cancer occurs when aberrant cells divide uncontrollably and can infiltrate adjacent tissues, travelling through the lymphatic and circulatory systems to other parts of the body (Nabi and Le 2021). Specifically, colon cancer (CC) is one of the deadliest malignant diseases, with significant prevalence and death rates (Li and Lai 2009). In particular, CC develops due to alterations in the normal colonic epithelium, including the development of adenomatous polyps that can multiply and enlarge, resulting in genetic and epigenetic mutations that accumulate over time (Kasi et al. 2020). Most studies report that 5% of CC are caused by genes that a person inherits, mainly through conditions such as Lynch syndrome or familial adenomatous polyposis (FAP). The majority of CCs are random (Xiao et al. 2019).

Clinically, the most frequently encountered symptoms in CC are constipation and abdominal pain. Additionally, bloating and abdominal

distension are significant clinical indicators, particularly in distal CC (Hirai et al. 2016). The global burden of CC is expected to rise by 60%, reaching roughly 2.2 million new cases and 1.1 million fatalities annually by 2030 (Wong et al. 2021). Similarly, like humans, animals are also affected, including dogs, and share common illnesses with humans, such as an increase in tumor-related colorectal disorders. In dogs, carcinoma of the colon accounts for around 60% of large intestine tumors (Herstad et al. 2021). Another study found spontaneous colon tumors commonly known as adenocarcinomas in dogs, which exhibit invasive development and potential for progression similar to those in humans (Wang 2019).

Various treatment protocols, including chemotherapy and radiotherapy, have been adopted to treat this lethal disorder. Chemotherapy is a conventional cancer treatment that uses chemicals to either kill or reduce the growth of cancer cells, but it can also cause side effects by affecting rapidly dividing normal cells, as shown in Fig.




Fig. 1. Toxicity of chemotherapy

1 (Bahadoer et al. 2021). Neoadjuvant chemotherapy, while beneficial in tumor reduction, carries significant risks such as chemotoxicity, surgical delays, and complications such as intestinal obstruction or perforation (Gosavi et al. 2021). A study reported chemotherapy in dogs and their adverse effects, like vomiting, diarrhea, neutropenia, and inappetence (Cunha et al. 2017). In another study, chemotherapy adverse effects were recorded at least once in 124 canines, with serious consequences reported in fifty dogs. Twenty-three of them suffered gastrointestinal problems, while thirty-one dogs had myelotoxicity consequences. Severe adverse effects resulted in the hospitalization of thirty-seven dogs, the cessation of chemotherapy in twelve dogs, and the euthanasia or mortality of nine dogs (Chavalle et al. 2022). Other research demonstrated that epirubicin treatment in feline patients bearing tumors has been linked to a variety of side effects, the most notable of which include gastrointestinal toxicity, anorexia, and lethargy. In addition, a subgroup of cats demonstrated epiphora, upper respiratory symptoms, and immune system disorders such as hypersensitivity (Elliott et al. 2025). The most prevalent adverse effect of chemotherapy in feline recorded was neutropenia, which limit dose. Human patients and pet animal owners may also experience financial hardship as a result of chemotherapy because of the high expense of supportive care, drugs, and treatment (Nelson et al. 2020). Mode of action and limitations of most common chemotherapeutic agents is given in Table 1.

Radiotherapy is another significant clinical option for CC in addition to surgery and chemotherapy, particularly for patients with intermediate or advanced CC who are not fit for chemotherapy and have no likelihood of a successful outcome from surgery (Tan et al. 2022). However, its efficacy is limited due to the low radio-sensitivity of CC and the high risk of collateral damage to surrounding normal tissues. Radiation can cause elevated levels of pro-inflammatory cytokines, which can lead to tissue damage in non-tumoral areas (Ball et al. 2017). According to research, conventional fractionated definitive radiotherapy (CFDRT) caused moderate to severe acute cutaneous and gastrointestinal toxicity, with late consequences such as colorectal

strictures, but hyper-fractionated radiotherapy caused lesser gastrointestinal symptoms such as colitis or diarrhoea in canines (Murakami and Rancilio 2025). The FLASH Radiotherapy for canines with mouth tumors is successful, although it generates substantial severe complications, particularly osteoradionecrosis when bone is in the course of the treatment field. Other concerns comprised necrosis and mucosal ulcers (Børresen et al. 2023). Similarly, another study found that acute radiation-induced negative impacts appeared in the skin and inside the mouth of dogs. Acute ocular adverse reactions included keratoconjunctivitis sicca (Mayer et al. 2019). Another study revealed that cats with sinonasal malignancies treated with radiotherapy applying a cyclical hypo-fractionated strategy obtained satisfactory tumour control but encountered moderate toxicities such as leukotrichia, alopecia, and ocular discharge (Frezoulis et al. 2022). Research demonstrated that in felines with squamous cell carcinoma of the mouth, radiation combined with zoledronate provided therapeutic advantages but also induced widespread acute toxicities such as dermatitis, mucositis, hyper-salivation, lethargy, and anorexia (Lundberg et al. 2022).

On the other hand, nanotechnology advances science and engineering by manipulating materials at the nanoscale from 1-100 nm and has demonstrated significant potential in medical applications, particularly in cancer therapy (Gowda et al. 2024). Nanomaterials are increasingly considered as the most effective therapeutic agents against a broad range of disorders (Mehwish et al. 2024). Nanoparticles (NPs) can improve cancer therapy by accurately delivering anticancer medications to tumour areas (Banazadeh et al. 2023; El-Dawy et al. 2023). Additionally, NPs have demonstrated a wide range of biomedical properties, such as antibacterial, anti-inflammatory (Ibrahim et al. 2024; Waliaveettil and Anila 2024), anticoagulant (Yenurkar et al. 2025), antioxidant (Samrot et al. 2022), and anti-diabetic activities (Loyola-Leyva et al. 2025). NPs can be formulated by using various sources, including artificial synthesis via top-down and bottom-up processes, as well as from the environment via volcanic ash, dust storms, anthropogenic, and other natural processes (Chimbekujwo et al. 2024; Ali et al. 2025). NPs can be synthesized using various techniques, including chemical methods (sol-gel, hydrothermal, solvothermal, vapour synthesis) (Khan 2020; Sati et al. 2025), biological methods (microbial, plant-based synthesis) (Alsaiairi et al. 2023; Akhreim et al. 2024), and mechanical methods (milling, mechanical alloying) (Suryanarayana et al. 2022; Zhao et al. 2024).

Nanotechnology is also utilized for the treatment of pets. For instance, the nanorods of gold were utilized in photothermal treatment to treat breast cancer in cats. Hyaluronic acid nanomaterials coated with cisplatin and paclitaxel were used against dogs with oral sarcoma and glandular cancer (Al-obaidi et al. 2024). Similarly, another study reported biomedical applications of AgNPs that displayed significant antibiofilm activity against *Staphylococcus pseudintermedius*, which was isolated from dogs with otitis externa. The antifungal action of AgNPs was demonstrated against the fungal dermatophyte *Microsporum canis*, which caused ringworm in both dogs and cats (Frippiat et al. 2025).

In recent years, plant-derived nanoagents have emerged as promising candidates for colon cancer treatment due to their biocompatibility, targeted delivery, and ability to enhance the therapeutic potential of phytochemicals (López-Cabanillas Lomelí et al. 2024). For example, *Curcuma longa* (turmeric) NPs have shown enhanced cytotoxicity against CC cells through ROS generation and

| Table 1. Modes of action and limitations of conventional chemical drugs in the treatment of colon cancer | | | | | | |
|--|---|----------------------|--|--|--|--|
| Chemical drug | Chemical formula | Brand | Composition | Mode of action | Limitations | References |
| 5-fluorouracil | $C_4H_3FN_2O_2$ | Adrucil | 5-FU, a pyrimidine analogue, forms by fluorinating uracil. | Disrupts deoxynucleotide pool. Impairing DNA fragmentation and RNA synthesis. | Myelosuppression, chemo-resistance, genetic and epigenetic variation, gastrointestinal toxicity. | (Vodenkova et al. 2020) |
| Capecitabine | $C_{15}H_{22}FN_3O_6$ | Xeloda | Transformed by the body into its active form, 5-fluorouracil. | Converting capecitabine into 5FU, thymidine phosphorylase inhibits DNA synthesis. | Adverse toxicity in clinical settings, bioavailability issues, and limited efficacy. | (Masuda et al. 2017; Adebayo et al. 2023; Pouya et al. 2023) |
| Oxaliplatin | $C_8H_{14}N_2O_4$ Pt. | Eloxatin (by Sanofi) | Platinum-based drug coordinated to two amine groups. | DNA cross-links, prevent transcription and DNA replication and cancer cells die. | Peripheral neuropathy, limited efficacy. | (Ma et al. 2021; Žok et al. 2021) |
| Irinotecan | $C_{20}H_{24}N_2O_5$ | Camptosar | Camptothecin, lactone ring, piperidine ring, active metabolite SN38. | DNA to form a ternary complex with topoisomerase I, DNA strands leading to apoptosis. | Neutropenia, diarrhoea, tumor relapse. | (Liu et al. 2022; Saurav et al. 2024) |
| Cisplatin | $PtCl_2(NH_3)_2$ | Platinol | Cis-diamminedichloroplatinum (II) square planer geometry, yellow–orange crystalline. | DNA cross-links, cisplatin prevents replication and induces apoptosis. | Dose-limiting toxicity, nephrotoxicity, cardiovascular issues, chemoresistance | (Casanova et al. 2021; Rottenberg et al. 2021; Ranasinghe et al. 2022) |
| Bevacizumab | $C_{6638}H_{10160}N_{1720}O_{2108}S_{44}$ | Avastin | 4 polypeptide chains, a chimeric monoclonal antibody, molecular weight of almost 149 KDa. | Preventing angiogenesis, Block VEGF, especially in metastatic colon cancer. | Impaired chemosensitivity, survival disparities, biological resistance, and limited effectiveness. | (You et al. 2020; Filippo et al. 2021; Taïeb et al. 2021) |
| Cetuximab | $C_{6484}H_{10042}N_{1732}O_{202353}$ | Erbitux | Two N-linked glycosylation Asn 88, 229, glycosylation features α 1-6 fucosylated structures. | Inhibits the attachment of Epidermal Growth Factor (EGF) by binding to the cell's EGF Receptor. | Induces mutations in HRAS, KRAS, and NRAS genes, change signalling pathways | (Váradí et al. 2020; Wu et al. 2020) |
| Fruquintinib | $C_2H_{19}N_3O_5$ | FRUZAQLA | C-O coupling of 4-chloro-6,7-dimethoxyquinazoline , 6-hydroxy-N, 2-dimethylbenzofuran-3-carbonyl amide | Obstruct the proliferation of colon cancer, modulation of epithelial-mesenchymal transition (EMT). | Gastrointestinal diseases, hypertension, and tiredness. | (Syaj and Saeed 2024; Song et al. 2025) |

apoptosis induction (Venkatadri et al. 2020). Similarly, *Camellia sinensis* (green tea) based NPs have demonstrated significant tumor suppression via modulation of Wnt/ β -catenin and NF- κ B signaling (Letchumanan et al. 2025). In comparison, *M. oleifera* is also renowned for its diverse range of phytochemicals, which demonstrate unique biological activities (Hegazy et al. 2023; Bagheri et al. 2024; Camilleri and Blundell 2024). It is a medicinal plant from the family Moringaceae and known by common names, such as drumstick tree and horseradish tree (Klimek-Szczykutowicz et al. 2024). Moringa has been used as an efficient and well-known therapeutic agent in traditional medicine for centuries (Bebas et al. 2023). Moreover, among the 13 species of the Moringa genus, *M. oleifera* is the most researched and utilised species due to its pharmacological and phytochemical profile that is relevant to human health (Ma et al. 2020; Hamada et al. 2024). Among the bioactive substances of Moringa are the potent antioxidant vitamins A and C (Khan et al. 2023; Arshad et al. 2025) and polyphenolic compounds,

such as kaempferol, quercetin, glycosides, terpenoids, tannins, and Saponins (Xie et al. 2024). The large levels of these antioxidants in Moringa determine its antioxidant activities (Garofalo et al. 2024), resulting in significant anticancer capabilities (Szlachetka et al. 2020) as well as hypotensive (Menichetti et al. 2025), anti-inflammatory (Shahbaz et al. 2024; Imran et al. 2023), antibacterial (El-Sherbiny et al. 2024), anti-ulcerous (Ibrahim and Al-Qadhi 2025), hypoglycaemic (Sahoo et al. 2024), and hypocholesterolaemic properties (Munir et al. 2025). For instance, the aqueous and methanol extracts of *M. oleifera* leaves have demonstrated a strong cytotoxic effect against various cancer cell lines, such as human HCT-116 colon cancer, murine melanoma B-16, and human colon carcinoma (Pappas et al. 2021).

In rats with DMBA-induced mammary cancer, the aqueous extract of *M. oleifera* leaves and benzyl isothiocyanate dramatically suppressed tumour and decreased serum levels of IL-1 β (Rojas-Armas et al. 2024). Similarly, research reported that Wistar rats with oral cancer were used

to examine the effects of *M. oleifera* leaf extract. *M. oleifera* limited oral cancer by lowering vascular endothelial growth factor (VEGF) and preventing the growth of blood vessels (Hartono et al. 2019). Another study evaluated that extract from *M. oleifera* leaves and pods improved blood counts and dramatically decreased chemically caused skin cancer in mice (Saradha et al. 2024). Moreover, another research found that the ethanol-based extract of *M. oleifera* has anti-leukemic properties that reversed the severe anaemia and significant leucocytosis induced by benzene (Akanni et al. 2014).

M. oleifera has been widely used in the synthesis of various NPs, such as gold (Au), silver (Ag), iron (Fe), copper oxide (CuO), zinc oxide (ZnO), magnesium oxide (MgO), nickel oxide (NiO), bismuth, and cerium oxide (CeO) (Aslam et al. 2023; Perumalsamy et al. 2024). Studies revealed that *M. oleifera*-synthesized silver NPs have strong, broad-spectrum antimicrobial properties (Mohammed and Hawar 2022), while AuNPs derived from *M. oleifera* exhibited substantial antidiabetic, antioxidant, and anticancer effects (Kiran et al. 2021). ZnONPs demonstrated moderate to good antibacterial efficacy (Kalaiyarasi et al. 2023; Maqsood et al. 2023), and CuONPs displayed selective cytotoxicity against cancer cells like MCF-7 breast cancer cells, while sparing normal cells such as NIH/3T3 (Suardana et al. 2024; Barani et al. 2024). This selectivity makes CuO NPs a promising therapeutic option for minimising side effects during chemotherapy for cancer (Sarani et al. 2024). Similarly, MgO NPs demonstrated powerful antioxidant properties, which effectively scavenge oxidant radicals and reactive oxygen species (ROS). One of their potential therapeutic applications is treating diseases associated with oxidative stress, such as cancer and cardiovascular diseases. MgONPs have displayed dose-dependent toxicity against PA-1 cancer cells (Vijayakumar et al. 2023). Thus, the inclusion of both Moringa extracts and Moringa-derived nanoparticles provides a comprehensive view of its therapeutic potential. While extracts offer natural bioactive compounds, nanoparticles enhance bioavailability, targeting efficiency, and anticancer activity, making them promising candidates for colon cancer therapy. This review critically explores the anticancer mechanisms and potential applications of *Moringa oleifera* and its biosynthesized nanoparticles in the treatment of CC, with particular attention to their molecular targets, pharmacodynamics, and future research directions in humans and animals.

2. Synthesis of Moringa nanoparticles

The biofabrication of metal NPs using Moringa plant extract consists of three important steps, as illustrated in Fig. 2 (Barman et al. 2023). The process begins with the reduction phase, during which the metal ions are reduced to form small clusters of metal atoms, which are called the primary particles (Virk et al. 2023). This is followed by the growth phase, where these initially unstable particles undergo heterogeneous nucleation and subsequently aggregate into larger, more thermodynamically stable structures (Perumalsamy et al. 2024; Sun et al. 2024). The final step is termination, which marks the point where these NPs attain their definitive morphology and stability. This structural stabilization is largely attributed to the Moringa plant extract, which acts as both a reducing and capping agent, effectively preventing further agglomeration and maintaining nanoparticle integrity (Vidaarth et al. 2024).

3. Mechanism of action of Moringa and its NPs

Moringa and its biosynthesized NPs exhibit significant anticancer




Fig. 2. Biosynthesis of nanoparticles from *Moringa oleifera*

properties through the induction of cell cycle arrest, apoptosis, oxidative stress, and modulation of oncogenic signalling pathways in colon cancerous cells, as illustrated in Fig. 3.




Fig. 3. Mechanisms of action of nanoparticles synthesized from *Moringa* against colon cancer

3.1. Induction of cell cycle arrest

Cell cycle arrest occurs when oxidative damage and redox imbalance exceed the cellular tolerance threshold. This stress causes DNA damage and eventually stops the cell cycle, which prevents the multiplication of cancerous cells (Hernandes et al. 2023). *M. oleifera* extracts have antiproliferative properties due to isothiocyanates produced from glucosinolate hydrolysis. These chemicals triggered apoptosis and

disrupted the cell cycle by affecting signalling pathways like NF- κ B (Cuellar-Núñez et al. 2020). Moringa peptides promoted Caco-2 cell cycle arrest, mostly through membrane rupture and internal interaction with cancer-related proteins and DNA (Avilés-Gaxiola et al. 2024). Silver (Ag) NPs derived from *M. oleifera* leaves showed strong cytotoxic activity against SW480 and HCT116 colon cancer cells by supporting their ability to effectively limit cancer cell proliferation (Althomali et al. 2022). The study found that *M. oleifera* leaf extract supplemented with Ag NPs demonstrated potent anti-cancer properties against azoxymethane-induced CC in rats, leading to improved biological efficiency, potentially causing cell cycle arrest in cancer cells (Aboulthana et al. 2021).

3.2. Induction of apoptosis

Apoptosis is a key mechanism through which tumor cells undergo cell death. Oncological treatment is greatly dependent on apoptosis since many pharmacological agents target the induction of apoptosis in cancer cells to decrease tumor volume and inhibit metastasis (Xie et al. 2020). The extract of *M. oleifera* induces apoptosis in HT29 CC cells by disrupting mitochondrial membrane potential, a pivotal event in the apoptosis process (Reda et al. 2020). Furthermore, the anti-proliferative effect of *M. oleifera* Lam. leaf extract was attributed to the inhibition of ERK1/2 phosphorylation, a key signaling pathway involved in cellular proliferation and survival, which enhances apoptosis in cancer cells (Tragulpakseerojn et al. 2017). Moreover, Cuellar-Núñez et al. (2020) observed that *M. oleifera* extract increases apoptosis by restricting the AKT Signaling pathway in HCT-116. A similar trend was demonstrated in another study by Kraiphet et al. (2018), where boiled *M. oleifera* pods induced apoptosis in colon cancerous cells, mediated by mitochondria in the AOM/DSS mouse model. Increased BAX and decreased BCL-2 values triggered tumor cell death and reduced metastasis.

Similarly, Ag NPs Moringa leaf powder downregulated oncogenes that manage parts of the cell cycle, cell growth, and invasiveness of cancer cells such as Ki-67, Wnt, β -catenin, Cyclin D1, TGF- β , and Snail, mainly through ROS production pathways in CC cells (Susanto et al. 2024). NiO NPs synthesized using *M. oleifera* caused overproduction of ROS and oxidative stress in the body, leading to a significant apoptosis in CC cells (Ezhilarasi et al. 2016). *M. oleifera* Ag NPs exhibited very high toxicity to HCT-116 cells with an IC₅₀ of 6.51 μ g/ml and it causes cell death by triggering the cascade of apoptosis (Abdel-Rahman et al. 2022). Moreover, Ibrahim et al. (2022) observed that *M. oleifera* extract and *M. oleifera* extract-Ag NPs, separately and together, significantly increased the number of apoptotic nuclei and upregulated the tumor-suppressor p53 protein in HT-29 human CC cells (Ibrahim et al. 2022).

3.3. Induction of Oxidative stress

According to Hayes et al. (2020), a high amount of reactive oxygen species (ROS), such as hydroxyl radicals, hydrogen peroxide (H₂O₂), and superoxide, compared to antioxidant defense capacity, results in various diseases, including cancer. Furthermore, *M. oleifera* triggered increased oxidative stress in HT29 CC cells by increasing ROS production and, therefore, resulted in impaired mitochondrial activity, reduced ATP production, and subsequent apoptotic cell death (Reda et al. 2020). These effects were further enhanced by the hexane fraction of *M. oleifera* extract (Jinghua et al. 2018). The exposure to glucosinolate-rich hydrolysed extract (GEH) of *M. oleifera* induced oxidative stress and subsequent apoptosis in CC cells (Shafiq et al. 2024; Cuellar-Núñez et al. 2020). Ag NPs synthesized using *M. oleifera* modified the key

genes related to pathways linked to cell proliferation, DNA damage, and oxidative stress (Avilés-Gaxiola et al. 2024). Furthermore, the Moringa Ag nano-extracts restored biochemical parameters to their normal values, thereby reducing the side effects of oxidative stress in azoxymethane (AOM)-induced colorectal cancer models (Aboulthana et al. 2021).

3.4. Oncogenic signalling pathway suppression

Oncogenic signalling pathways, such as PI3K/Akt, NF- κ B, and ERK, are upregulated in cancer, promoting tumorigenesis, metastasis, and resistance to therapy (Sanchez-Vega et al. 2018). The *M. oleifera* extract was shown to interfere with the NF- κ B and ERK pathways and simultaneously activate Nrf2 antioxidant defence system, thereby hindering the growth and maturation of CC cells (Sodvadiya et al. 2020). According to Tragulpakseerojn et al. (2017), the *M. oleifera* extract was found to restrain the growth of HCT116 cells by downregulating the ERK1/2 phosphorylation and AKT expression. The, *M. oleifera*-AgNPs altered the expression of key genes involved the development of colon carcinogenesis, such as downregulation of LRP6 and upregulation of LRP5 expression (Althomali et al. 2022). Similarly, downregulation of Ki-67 gene expression, associated with cancer cell growth, was observed on treatment with increasing concentrations of *M. oleifera* leaf powder-AgNPs, with effective suppression of the survival of colorectal cancer cells at a concentration of 1414 μ g/mL (Susanto et al. 2024). Furthermore, Sayed et al. (2021) revealed that ZnONPs interrupted PI3K/Akt and NF- κ B signalling, inhibiting cell growth and causing apoptosis in cases of colorectal cancer. These NPs also disrupted angiogenesis and migration of endothelial cells, which curtailed the blood supply and metastasis of cancer (Liu et al. 2021). The mode of action of different Moringa extracts against colon cancer is given in Table 2.

4. Anticancer effects against colon cancer in animals

Researchers have investigated the anticancer properties of Moringa extracts and their NPs formulations against different kinds of cancers in animals. According to a study, lymphoma has been reported at high prevalence in cats and dogs, weakening their immune systems. However, *M. oleifera* induced the apoptosis of the cancerous cells by expressing the Caspase-3 gene when treating the EL4 murine lymphoma cell line at 40 μ g/ml (Shekarabi et al. 2025). Similarly, adenocarcinomas are also among the most frequent neoplasms reported in cats and dogs (Negoescu et al. 2025). Nevertheless, *M. oleifera* inhibited the growth of adenocarcinoma in urethane-induced lung cancer rats by upregulating glutathione, superoxide dismutase, EGFR-mRNA, and downregulating malondialdehyde (Ibrahim et al. 2023). Similarly, multiple studies have elaborated on the effect of *M. oleifera* extract against the CC. For instance, a study conducted by Phannasil et al. (2020) revealed that *M. oleifera* pods showed therapeutic potential against AOM/DSS-induced colon carcinogenesis in mice via regulating tumor-related proteomes. Similarly, Moringa leaf extract modulated AOM/DSS-associated CC in rodents through anti-inflammatory processes in colon tissues (Cuellar-Núñez et al. 2021). Furthermore, *M. oleifera* leaf extract alleviated colonic injury, which is a risk factor for CC, induced by sodium nitrate in a rat model by suppressing oxidative stress, hyperproliferation, and apoptosis, indicating its chemotherapeutic potential (Hassan et al. 2024). According to another study, in DMH-induced Sprague Dawley rats, the neoplastic lesion of CC was inhibited by *M. oleifera* leaf extract through lessened aberrant

Table 2. Modes of action of Moringa extracts against colon cancer

| Plant part | Extraction solvent | Dose | Cancer cell line/ Animal model | IC ₅₀ Value | Mode of action | References |
|------------|---------------------|---------------|-----------------------------------|---------------------------|--|--------------------------------|
| Leaf | Methanol | 0.55 mg/mL | HCT-116, HT-29 | 0.17 mg/mL, 0.19 mg/mL | Induce apoptosis by blocking the AKT Signalling pathway | (Cuellar-Núñez et al. 2020) |
| Leaf | dd-H ₂ O | 0.3mg/mL | HT-29 | - | Induce apoptosis by losing mitochondrial membrane potential | (Reda et al. 2020) |
| Leaf | 100% Methanol | 44.02 µg/mL | HCT-116 | - | Induce apoptosis by suppressing ERK1/2 phosphorylation and lowering pro-survival signals | (Tragulpakseerojn et al. 2017) |
| Pod | Water | 3.0% (diet) | Mouse model | - | Induce apoptosis via lowering BCL-2 levels and raising BAX expression | (Kraiphet et al. 2018) |
| Leaf | Methanol | 0.55mg/mL | HCT-116, HT-29 | 0.17 mg/mL, 0.19 mg/mL | Trigger cell cycle arrest by affecting signalling pathways like NF-Kb | (Cuellar-Núñez et al. 2020) |
| Leaf | Tris-HCL buffer | 500µg/mL | Caco-2 | - | Promote cell cycle arrest through membrane rupture and internal interaction with cancer-related proteins and DNA | (Avilés-Gaxiola et al. 2024) |
| Leaf | Hexane | 100-200 µg/mL | HT-29 | - | Oxidative stress triggers mitochondrial apoptosis | (Jinghua et al. 2018) |
| Leaf | Methanol | 0.55 mg/mL | HCT-116, HT-29 | 0.17 mg/mL, 0.19 mg/mL | Oxidative stress leads to mitochondrial damage and apoptosis | (Cuellar-Núñez et al. 2020) |
| Leaf | dd-H ₂ O | 1.8 mg/mL | HT-29 | - | Induce oxidative stress | (Reda et al. 2020) |
| Leaf | Methanol | 6% (w/w) | Mice model | | Suppressing NF-κB and ERK signalling pathways | (Sodvadiya et al. 2020) |
| Leaf | 100% Methanol | 19 µg/mL | HCT-116 | - | Downregulation of ERK ½ phosphorylation decreases AKT expression | (Tragulpakseerojn et al. 2017) |

crypt foci, regulation of liver/kidney markers, and rebuilding tissue architecture, thus offering chemopreventive and protective action versus carcinogenesis (Kumawat and Une 2024). Moreover, the CC progression was reduced by *M. oleifera* AgNPs in male Wistar rats through inhibiting angiogenesis and cell invasion. MO-AgNPs also inhibited endothelial tube formation, micro-vessel sprouting, and spheroid growth, therefore, reducing vascularization of the tumors, cancerous invasion, and metastasis (Al-Shalabi et al. 2025). According to another study, in an AOM-induced rat model, *M. oleifera* nano-extract inhibited CC by reducing biochemical parameters to normal, increasing the expression of tumor protein 53 and Adenomatous polyposis coli (APC), restoring antioxidant enzyme gene patterns, and preserving the histology of the colonic tissue (Aboulthana et al. 2021). Furthermore, in the rat model, *M. oleifera* leaf silver nano-extract repressed CC progression by complementing antioxidant defence, escalating polyphenolic level, enhancing free radical scavenging action, and was further amplified with the higher cytotoxicity against CC cells via effective bioavailability of phytochemicals (Shousha et al. 2019; Luecha et al. 2024). Hence, *M. oleifera* and its NPs show significant potential for preventing colon cancer in animal studies by boosting antioxidant defences, promoting apoptosis, reducing inflammation, and inhibiting angiogenesis and metastasis, underscoring their potential as natural, multi-targeted agents against cancer. However, there is still a limited amount of research that specifically targets Moringa extract and NP-based treatments for colon cancer in domestic animals.

5. Challenges and limitations

The variability in cytotoxic efficacy between colon cancer cell lines (HCT 116 more sensitive than Caco-2) with Moringa leaf extract-loaded PLGA-CS-PEG nanoparticles was demonstrated by a study showing dose-dependent decreases in viability of HCT 116 but resistance in Caco-2 cells. The bioavailability and delivery challenges are linked to the use of nanoparticles like PLGA-CS-PEG that improve stability and

controlled release, but comprehensive in vivo data are still limited, as referenced in studies including those that tested nanocomposites of Moringa extracts (Abd-Rabou et al. 2017). Toxicity and safety profiles show minimal effects on normal cells in some studies; for example, cytotoxicity was selective toward cancer cells with lower impact on normal cells like BHK-21 or CD34+ hematopoietic stem cells. This suggests a potentially favourable safety profile, but more data is needed. Standardization issues arise from the complex phytochemical composition, as seen in studies comparing various Moringa extracts (ethanolic, aqueous, sequential extraction) with differential cytotoxic effects due to varying active metabolites. Mechanistic insights into apoptosis and gene expression modulation are still developing. Still, studies have shown that Moringa leaf extracts and their nanoparticles induce apoptosis and cell cycle arrest through molecular pathways involving caspase and BID proteins in cancer cells (Khor et al. 2020).

6. Future perspectives

Future research on *Moringa oleifera* and its nanoparticle (NP) derivatives should focus on four critical directions. First, preclinical and clinical trials shall be mandatory to evaluate the long-term safety, pharmacokinetics, and therapeutic efficacy of Moringa and its NPs in the treatment of colon cancer. Second, a deeper understanding of their molecular mechanisms is needed through advanced studies targeting key signalling pathways and gene expression profiles. Third, optimising Moringa NP synthesis processes to improve their stability, biocompatibility, and tumor targeting capabilities. Fourth, investigating Moringa-based combination therapies with other anti-cancer medications or treatments to yield synergistic effects, potentially overcoming drug resistance and improving therapeutic outcomes. Finally, investigating the potential of Moringa and its NPs in other cancer types may reveal broader anticancer potentials, supporting their development as versatile, multi-targeted therapeutic agents.

7. Conclusion

Moringa and its nano-formulations exhibited powerful antiproliferative properties in colon cancer by inducing cell cycle arrest and apoptosis through ROS-mediated oxidative stress, while blocking oncogenic pathways, such as Wnt/ β -catenin. Moringa-based nanoparticles, particularly AgNPs, enhance these effects by amplifying cytotoxicity, modulating gene expression, and inhibiting proliferation and metastatic indicators. Despite promising *in vitro* and *in vivo* findings, the translation of these outcomes to clinical practice is hampered by the lack of clinical trials. Therefore, extensive *in vivo* research and well-controlled clinical trials in humans and animal models are essential to validate the therapeutic efficacy and safety of Moringa and its NPs. Collectively, the multi-targeted mechanisms of action underscore Moringa's potential as a promising candidate in colon cancer therapy and warrant further investigation and development to fill the treatment gaps in chemotherapy-resistant CC.

Declarations

Funding: Not applicable

Conflict of interest: Authors declare no conflicts of interest

Acknowledgements: None

References

- Abd-Rabou AA, Abdalla AM, Ali NA, Zoheir KM. (2017). *Moringa oleifera* root induces cancer apoptosis more effectively than leave nanocomposites and its free counterpart. *Asian Pacific Journal of Cancer Prevention* 18(8): 2141. <https://doi.org/10.22034/APJCP.2017.18.8.2141>
- Abdel-Rahman LH, Al-Farhan BS, Abou El-ezz D, Abd-El Sayed MA, Zikry MM, Abu-Dief AM. (2022). Green biogenic synthesis of silver nanoparticles using aqueous extract of *Moringa oleifera*: access to a powerful antimicrobial, anticancer, pesticidal and catalytic agents. *Journal of Inorganic and Organometallic Polymers and Materials* 32(4): 1422-1435. <https://doi.org/10.1007/s10904-022-03194-0>
- Aboulthana WM, Shousha WG, Essawy EAR, Saleh MH, Salama AH. (2021). Assessment of the anti-cancer efficiency of silver *Moringa oleifera* leaves nano-extract against colon cancer induced chemically in rats. *Asian Pacific Journal of Cancer Prevention* 22(10): 3267. <https://doi.org/10.31557/APJCP.2021.22.10.3267>
- Adebayo AS, Agbaje K, Adesina SK, Olajubutu O. (2023). Colorectal cancer: Disease process, current treatment options, and future perspectives. *Pharmaceutics* 15(11): 2620. <https://doi.org/10.3390/pharmaceutics15112620>
- Akanni EO, Adedeji AL, Adedosu OT, Olaniran OI, Oloke JK. (2014). Chemopreventive and anti-leukemic effects of ethanol extracts of *Moringa oleifera* leaves on Wistar rats bearing benzene-induced leukemia. *Current Pharmaceutical Biotechnology* 15(6): 563-568. <https://doi.org/10.2174/1389201015666141226101731>
- Akhreim AA, Gaballa MF, Sulaiman G, Attitalla IH. (2024). Biofertilizers production and climate changes on environmental prospective applications for some nanoparticles produced from some microbial isolates. *International Journal of Agriculture and Biosciences* 13(2): 196- 203. <https://doi.org/10.47278/journal.ijab/2024.094>
- Al-Obaidi RM, Shaker AS, Ameen QA, Arif ED, Khidhir ZK, Fadhl HNM, Hussein RH, Arif SK. (2024). Applications and perspectives of nanotechnology in veterinary medicine. In: Rubio VGG, Khan A, Altaf S, Saeed Z and Qamar W (eds), *Complementary and Alternative Medicine: Nanotechnology-I*. Unique Scientific Publishers, Faisalabad, Pakistan, pp: 1-10. <https://doi.org/10.47278/book.CAM/2024.006>
- Al-Shalabi R, Lim V, Al-Deeb I, Kilus M, Samad NA. (2025). Anti-angiogenic effects of *Moringa oleifera* silver nanoparticles on endothelial cells: in vitro and ex vivo studies. *Exploration of Targeted Anti-tumor Therapy* 6: 1002332. <https://doi.org/10.37349/etat.2025.1002332>
- Ali SM, Alhadhrami NA, Emran KM. (2025). Bottom-up and top-down fabrication processes of polymer and two-dimensional nanocomposites. In: *Polymers and Two-Dimensional Nanocomposites*. Woodhead Publishing, pp. 61-82. <https://doi.org/10.1016/B978-0-443-14131-7.00004-3>
- Alsaiair NS, Alzahrani FM, Amari A, Osman H, Harharah HN, Elboughdiri N, Tahoon MA. (2023). Plant and microbial approaches as green methods for the synthesis of nanomaterials: synthesis, applications, and future perspectives. *Molecules* 28(1): 463. <https://doi.org/10.3390/molecules28010463>
- Althomali A, Daghestani MH, Basil Almukaynizi F, Al-Zahrani SA, Awad MA, Merghani NM, Bhat RS. (2022). Anti-colon cancer activities of green-synthesized *Moringa oleifera*-AgNPs against human colon cancer cells. *Green Processing and Synthesis* 11(1): 545-554. <https://doi.org/10.1515/gps-2022-0074>
- Arshad MT, Maqsood S, Ikram A, Gnedeka KT. (2025). Recent perspectives on the pharmacological, nutraceutical, functional, and therapeutic properties of *Moringa oleifera* plant. *Food Science & Nutrition* 13(4): e70134. <https://doi.org/10.1002/fsn3.70134>
- Aslam N, Ali A, Sial BE, Maqsood R, Mahmood Y, Mustafa G, Sana A. (2023). Assessing the dual impact of zinc oxide nanoparticles on living organisms: beneficial and noxious effects. *International Journal of Agriculture and Biosciences* 12(4): 267-276. <https://doi.org/10.47278/journal.ijab/2023.076>
- Avilés-Gaxiola S, Contreras-Angulo LA, García-Aguilar I, Heredia JB. (2024). *Moringa oleifera* Lam. Leaf Peptides: Antioxidant and Antiproliferative Activity in Human Colon Cancer Caco-2 Cell Line. *Antioxidants* 13(11): 1367. <https://doi.org/10.3390/antiox13111367>
- Bagheri E, Shori AB, Peng CW, Baba AS, Alzahrani AJ. (2024). Phytochemical analysis and medicinal properties of some selected traditional medicinal plants. *International Journal of Agriculture and Biosciences* 13(4): 689-700. <https://doi.org/10.47278/journal.ijab/2024.177>
- Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CA, Putter H, Kranenbarg EMK, Silveira ML. (2021). Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. *The Lancet Oncology* 22(1): 29-42. [https://doi.org/10.1016/S1470-2045\(20\)30568-7](https://doi.org/10.1016/S1470-2045(20)30568-7)
- Ball B, Zeidan A, Gore SD, Prebet T. (2017). Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. *Leukemia & Lymphoma* 58(5): 1022-1036. <https://doi.org/10.1080/10428194.2016.1259034>
- Banazadeh M, Behnam B, Ganjooei NA, Gowda BJ, Kesharwani P, Sahebkar A. (2023). Curcumin-based nanomedicines: A promising avenue for brain neoplasm therapy. *Journal of Drug Delivery Science and Technology* 89: 105040. <https://doi.org/10.1016/j.jddst.2022.105040>
- Barani M, Mir A, Roostaei M, Sargazi G, Adeli-Sardou M. (2024). Green synthesis of copper oxide nanoparticles via *Moringa peregrina* extract incorporated in graphene oxide: evaluation of antibacterial

- and anticancer efficacy. *Bioprocess and Biosystems Engineering* 47(11): 1915-1928. <https://doi.org/10.1007/s00449-024-03077-2>
- Barman A, Kotal A, Das M. (2023). Synthesis of metal based nano particles from *Moringa Olifera* and its biomedical applications: a review. *Inorganic Chemistry Communications* 158: 111438. <https://doi.org/10.1016/j.inoche.2023.111438>
- Bebas W, Gorda IW, Agustina KK. (2023). Spermatozoa quality of Kintamani dogs in coconut water-egg yolk diluent with addition of Moringa leaves and carrot extract. *International Journal of Veterinary Science* 12(3): 333-340. <https://doi.org/10.47278/journal.ijvs/2022.197>
- Børresen B, Arendt ML, Konradsson E, Jensen KB, Bäck SÅ, af Rosenschöld PM, Petersson K. (2023). Evaluation of single-fraction high-dose FLASH radiotherapy in a cohort of canine oral cancer patients. *Frontiers in Oncology* 13: 1256760. <https://doi.org/10.3389/fonc.2023.1256760>
- Camilleri E, Blundell R. (2024). A comprehensive review of the phytochemicals, health benefits, pharmacological safety and medicinal prospects of *Moringa oleifera*. *Heliyon* 10(6): e27807 <https://doi.org/10.1016/j.heliyon.2024.e27807>
- Casanova AG, Harvat M, Vicente-Vicente L, Pellicer-Valero ÓJ, Morales AI, López-Hernández FJ, Martín-Guerrero JD. (2021). Regression modeling of the antioxidant-to-nephroprotective relation shows the pivotal role of oxidative stress in cisplatin nephrotoxicity. *Antioxidants* 10(9): 1355. <https://doi.org/10.3390/antiox10091355>
- Chavalle T, Chamel G, Denoeux P, Lajoinie M, Sayag D, Berny P, Ponce F. (2022). Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs. *Veterinary and Comparative Oncology* 20(2): 393-403. <https://doi.org/10.1111/vco.12782>
- Chimbekujwo KI, Sani AR, Oyewole OA, Isibor PO. (2024). Sources of nanoparticles. In *Environmental Nanotoxicology: Combatting the Minute Contaminants*. Cham: Springer Nature Switzerland, pp. 41-58. https://doi.org/10.1007/978-3-031-21983-5_3
- Cuellar-Núñez ML, De Mejia EG, Loarca-Piña G. (2021). *Moringa oleifera* leaves alleviated inflammation through downregulation of IL-2, IL-6, and TNF- α in a colitis-associated colorectal cancer model. *Food Research International* 144: 110318. <https://doi.org/10.1016/j.foodres.2021.110318>
- Cuellar-Núñez ML, Loarca-Piña G, Berhow M, de Mejia EG. (2020). Glucosinolate-rich hydrolyzed extract from *Moringa oleifera* leaves decreased the production of TNF- α and IL-1 β cytokines and induced ROS and apoptosis in human colon cancer cells. *Journal of Functional Foods* 75: 104270. <https://doi.org/10.1016/j.jff.2020.104270>
- Cunha SCS, Silva FBF, Corgozinho KB, Da Silva KGC, Ferreira AMR. (2017). Adverse effects of chemotherapy in dogs. *World's Veterinary Journal* 7(3): 74-82. <http://dx.doi.org/10.5455/wvj.20170896>
- El-Dawy K, Saad S, Hussein MMA, Yahia R, Al-Gamal M. (2023). Naturally based nano formulation in metabolic and reproductive disorders: A review. *International Journal of Veterinary Science* 12(1): 7-17. <https://doi.org/10.47278/journal.ijvs/2022.142>
- El-Sherbiny GM, Alluqmani AJ, Elsehemy IA, Kalaba MH. (2024). Antibacterial, antioxidant, cytotoxicity, and phytochemical screening of *Moringa oleifera* leaves. *Scientific Reports* 14(1): 1-17. <https://doi.org/10.1038/s41598-024-80700-y>
- Elliott J, Serras AR, Amores-Fuster I, Blackwood L. (2025). Retrospective assessment of toxicity associated with epirubicin chemotherapy in 66 tumour-bearing cats. *Veterinary Oncology* 2(1): 15. <https://doi.org/10.1186/s44356-025-00029-0>
- Ezhilarasi AA, Vijaya JJ, Kaviyarasu K, Maaza M, Ayeshamariam A, Kennedy LJ. (2016). Green synthesis of NiO nanoparticles using *Moringa oleifera* extract and their biomedical applications: Cytotoxicity effect of nanoparticles against HT-29 cancer cells. *Journal of Photochemistry and Photobiology B: Biology* 164: 352-360. <https://doi.org/10.1016/j.jphotochem.2016.10.024>
- Filippo LDD, Dos Santos KC, Hanck-Silva G, de Lima FT, Gremiao MPD, Chorilli M. (2021). A critical review of biological properties, delivery systems and analytical/bioanalytical methods for determination of bevacizumab. *Critical Reviews in Analytical Chemistry* 51(5): 445-453. <https://doi.org/10.1080/10408347.2020.1743641>
- Frezoulis PS, Harper A, Mason SL. (2022). Use of a cyclical hypofractionated radiotherapy regime ('QUAD shot') for the treatment of feline sinonasal carcinomas. *Journal of Feline Medicine and Surgery* 24(12): 1212-1218. <https://doi.org/10.1177/1098612X211070737>
- Frippiat T, Art T, Delguste C. (2025). Silver nanoparticles as antimicrobial agents in veterinary medicine: Current applications and future perspectives. *Nanomaterials* 15(3): 202. <https://doi.org/10.3390/nano15030202>
- Garofalo G, Buzzanca C, Ponte M, Barbera M, D'Amico A, Greco C, Gaglio R. (2024). Comprehensive analysis of *Moringa oleifera* leaves' antioxidant properties in ovine cheese. *Food Bioscience* 61: 104974. <https://doi.org/10.1016/j.fbio.2024.104974>
- Gosavi R, Chia C, Michael M, Heriot AG, Warriar SK, Kong JC. (2021). Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. *International Journal of Colorectal Disease* 36(10): 2063-2070. <https://doi.org/10.1007/s00384-021-04056-6>
- Gowda BJ, Ahmed MG, Almoyad MAA, Wahab S, Almalki WH, Kesharwani P. (2024). Nanosponges as an emerging platform for cancer treatment and diagnosis. *Advanced Functional Materials* 34(7): 2307074. <https://doi.org/10.1002/adfm.202307074>
- Hamada FA, Sabah SS, Mahdy E, El-Raouf HAS, El-Taher AM, El-Leel OF, Randhir TO. (2024). Genetic, phytochemical and morphological identification and genetic diversity of selected *Moringa* species. *Scientific Reports* 14(1): 1-18. <https://doi.org/10.1038/s41598-024-79148-x>
- Hartono DRN, Sulisetyawati TIB, Jularso E. (2019). The potential effect of *Moringa oleifera* leaves extract on vascular endothelial growth factor expression in Wistar rat oral cancer cells. *Dental Journal* 52(2): 71-75. <https://doi.org/10.20473/j.djmk.v52.i2.p71-75>
- Hassan HM, Elsaed WM, Elzeiny D, Habotta OA, Eleraky ES, El Nashar EM, Hamza E. (2024). Modulatory effects of *Moringa oleifera* leaf extract on sodium nitrate-induced experimental colitis via regulation of P53, Ki-67 and PCNA biomarkers. *Tissue and Cell* 88: 102327. <https://doi.org/10.1016/j.tice.2024.102327>
- Hayes JD, Dinkova-Kostova AT, Tew KD. (2020). Oxidative stress in cancer. *Cancer cell* 38(2): 167-197. <https://doi.org/10.1016/j.ccell.2020.07.006>
- Hegazy SA, Abd Elmawla SM, Khorshed MM, Salem FA. (2023). Productive and immunological performance of small ruminants offered some medicinal plants as feed additives. *International Journal of Veterinary Science* 12(1): 120-125. <https://doi.org/10.47278/journal.ijvs/2022.163>

- Hernandes EP, Lazarin-Bidóia D, Bini RD, Nakamura CV, Cótica LE, de Oliveira Silva Lautenschlager S. (2023). Doxorubicin-loaded iron oxide nanoparticles induce oxidative stress and cell cycle arrest in breast cancer cells. *Antioxidants* 12(2): 237. <https://doi.org/10.3390/antiox12020237>
- Herstad KMV, Gunnes G, Rørtveit R, Kolbjørnsen Ø, Tran L, Skancke E. (2021). Immunohistochemical expression of β -catenin, Ki67, CD3 and CD18 in canine colorectal adenomas and adenocarcinomas. *BMC Veterinary Research* 17(1): 119. <https://doi.org/10.1186/s12917-021-02829-6>
- Hirai HW, Tsoi KKF, Chan JYC, Wong SH, Ching JYL, Wong MCS, Ng SC. (2016). Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies. *Alimentary Pharmacology & Therapeutics* 43(7): 755-764. <https://doi.org/10.1111/apt.13530>
- Ibrahim EH, Alshahrani MY, Ghramh HA, Alotheid H, Kilany M, Morsy K, Mohammed MEA. (2022). Potency of *Moringa oleifera* leaf extract and silver nanoparticles against immune, microbial and HT-29 colon cancer cells growth modulation. *Pakistan Journal of Pharmaceutical Sciences* 35(3). <https://doi.org/10.31218/pjps.v35i3.35669>
- Ibrahim ES, Abdalhamed AM, Arafa AA, Eid RH, Khalil HMA, Hedia RH, Dorgham SM, Hozyen HF. (2024). In vitro and in vivo antibacterial and antibiofilm efficacy of selenium nanoparticles against *Staphylococcus aureus* supported with toxicopathological and behavioral studies in rats. *International Journal of Veterinary Science* 13(4): 490-500. <https://doi.org/10.47278/journal.ijvs/2023.115>
- Ibrahim IA, Al-Qadhi HI. (2025). The anti ulcerogenic effect of sildenafil and Moringa on ulcers in rats. *Tissue and Cell* 93: 102685. <https://doi.org/10.1016/j.tice.2024.102685>
- Ibrahim MA, Mohamed SR, Dkhil MA, Thagfan FA, Abdel-Gaber R, Soliman D. (2023). The effect of *Moringa oleifera* leaf extracts against urethane-induced lung cancer in rat model. *Environmental Science and Pollution Research* 30(13): 37280-37294. <https://doi.org/10.1007/s11356-022-24813-9>
- Imran M, T Umer, HU Rehman, M Saleem, H Farooq. (2023). Anti-Inflammatory, immunomodulatory and antioxidant activities of allicin, vitamin C and doxycycline and their combination against *Pasteurella multocida* (a review). *Continental Veterinary Journal* 3(1): 9-16.
- Jinghua L, Linmei S, Ping H, Gothai S, Muniandy K, Kumar SS, Arulselvan P. (2018). Amelioration of oxidative stress through apoptosis-mediated pathway in colon cancer cells by hexane fraction of *Moringa oleifera* extract. *Pharmacognosy Magazine* 14(57s). https://doi.org/10.4103/pm.pm_597_16
- Kalaiyarasi C, Poonkothai M, Abirami S, Alaguprathana M, Marraiki N, Zaghoul NS. (2023). Zinc oxide nanoparticles fabrication using *Moringa oleifera* Lam. seed extract—Impact on phytotoxic, photocatalytic, and antimicrobial activities. *Applied Nanoscience* 13(3): 2187-2197. <https://doi.org/10.1007/s13204-023-03291-3>
- Kasi A, Handa S, Bhatti S, Umar S, Bansal A, Sun W. (2020). Molecular pathogenesis and classification of colorectal carcinoma. *Current Colorectal Cancer Reports* 16: 97-106. <https://doi.org/10.1007/s11888-020-00548-5>
- Khan FA. (2020). Synthesis of nanomaterials: Methods & technology. In: *Applications of Nanomaterials in Human Health*. 15-21. <https://doi.org/10.1201/9781003039548-2>
- Khan MTS, Z Khan, S Murtaza, M Afzal, A Mahmood, NU Khan. (2023). Therapeutic effects of medicinal plants on immunology and growth (a review). *Continental Veterinary Journal* 3(2): 43-54.
- Khor K, Joseph J, Shamsuddin F, Lim V, Moses EJ, Abdul Samad N. (2020). The cytotoxic effects of *Moringa oleifera* leaf extract and silver nanoparticles on human kasumi-1 cells. *International Journal of Nanomedicine* 15: 5661-5670. <https://doi.org/10.2147/IJN.S244834>
- Kiran MS, Kumar CR, Shwetha UR, Onkarappa HS, Betageri VS, Latha MS. (2021). Green synthesis and characterization of gold nanoparticles from *Moringa oleifera* leaves and assessment of antioxidant, antidiabetic and anticancer properties. *Chemical Data Collections* 33: 100714. <https://doi.org/10.1016/j.cdc.2020.100714>
- Klimek-Szczykutowicz M, Gawel-Beben K, Rutka A, Blicharska E, Tatarczak-Michalewska M, Kulik-Siarek K, Szopa A. (2024). *Moringa oleifera* (drumstick tree)—nutraceutical, cosmetological and medicinal importance: a review. *Frontiers in Pharmacology* 15: 1288382. <https://doi.org/10.3389/fphar.2024.1288382>
- Kraiphet S, Butryee C, Rungsipipat A, Budda S, Rattanapinyopitak K, Tuntipopipat S. (2018). Apoptosis induced by *Moringa oleifera* Lam. pod in mouse colon carcinoma model. *Comparative Clinical Pathology* 27: 21-30. <https://doi.org/10.1007/s00580-017-2696-5>
- Kumawat M, Une H. (2024). Effect of *Lactobacillus acidophilus*, calcium, and *Moringa oleifera* leaves extract co-administration can prevent chemical-induced carcinogenesis. *Arab Journal of Gastroenterology* 25(4): 421-436. <https://doi.org/10.1016/j.ajg.2024.07.015>
- Letchumanan D, Ibrahim S, Nagoor NH, Mohd Arshad N. (2025). Green synthesis of copper oxide nanoparticles using *Camellia sinensis*: anticancer potential and apoptotic mechanism in ht-29 and mcf-7 cells. *International Journal of Molecular Sciences* 26(15): 7267. <https://doi.org/10.3390/ijms26157267>
- Li FY, Lai MD. (2009). Colorectal cancer, one entity or three. *Journal of Zhejiang University Science B* 10(3): 219-229. <https://doi.org/10.1631/jzus.B0820408>
- Liu Y, Li X, Pen R, Zuo W, Chen Y, Sun X, Huang M. (2022). Targeted delivery of irinotecan to colon cancer cells using epidermal growth factor receptor-conjugated liposomes. *BioMedical Engineering Online* 21(1): 53. <https://doi.org/10.1186/s12938-022-01239-1>
- Liu Y, Zhou J, Li Q, Li L, Jia Y, Geng F, Yin T. (2021). Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma. *Advanced Drug Delivery Reviews* 172: 80-103. <https://doi.org/10.1016/j.addr.2021.05.003>
- López-Cabanillas Lomelí M, Tijerina-Sáenz A, García-Hernández DG, Hernández-Salazar M, Salas García R, González-Llerena JL, Heya MS. (2024). Colon cancer: overview on improved therapeutic potential of plant-based compounds using nanotechnology. *Scientia Pharmaceutica* 93(1): 1. <https://doi.org/10.3390/scipharm93010001>
- Loyola-Leyva A, Hernández-Vidales K, Ruiz-García J, Loyola-Rodríguez JP. (2025). Characterization of green synthesized nanoparticles with anti-diabetic properties. A systematic review. *Current Diabetes Reviews* 21(7): E200524230102. <https://doi.org/10.2174/1573399321666240523125843>
- Luecha P, Trunjaruen A, Suraporn S, Yaowachai W, Maneerattanarungroj P, Kunpratun N and Taratima W. (2024). Optimization of phytochemical content and DPPH scavenging activity from pokeweed (*Phytolacca americana* L.) callus using

- response surface models. *International Journal of Agriculture and Biosciences* 13(3): 356-366. <https://doi.org/10.47278/journal.ijab/2024.130>
- Lundberg AP, Tran Hoang C, Billhymer A, Selting KA. (2022). Combining radiation therapy with zoledronate for the treatment of osteo-invasive feline oral squamous cell carcinoma. *Veterinary and Comparative Oncology* 20(4): 788–796. <https://doi.org/10.1111/vco.12799>
- Ma L, Li X, Zhao X, Sun H, Kong F, Li Y, Xu F. (2021). Oxaliplatin promotes siMAD2L2-induced apoptosis in colon cancer cells. *Molecular Medicine Reports* 24(3): 629. <https://doi.org/10.3892/mmr.2021.12141>
- Ma Z F, Ahmad J, Zhang H, Khan I, Muhammad S. (2020). Evaluation of phytochemical and medicinal properties of *Moringa oleifera* as a potential functional food. *South African Journal of Botany* 129: 40-46. <https://doi.org/10.1016/j.sajb.2020.04.016>
- Maqsood R, Ali A, BE Sial, N Aslam, Y Mehmood, G Mustafa, T Sohail, M Farhab. (2023). In vivo and in vitro genotoxic effects of zinc oxide nanoparticles (ZnO NPs): A comprehensive review. *Continental Veterinary Journal* 3(2): 1-14.
- Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Toi M. (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *New England Journal of Medicine* 376(22): 2147-2159. <https://doi.org/10.1056/NEJMoa1613364>
- Mayer MN, DeWalt JO, Sidhu N, Mauldin GN, Waldner CL. (2019). Outcomes and adverse effects associated with stereotactic body radiation therapy in dogs with nasal tumors: 28 cases (2011–2016). *Journal of the American Veterinary Medical Association* 254(5): 602–612. <https://doi.org/10.2460/javma.254.5.602>
- Mehwish, Azam SE, Muzamail S. (2024). Unveiling the future: nanotechnology's role in advanced food packaging. *Agrobiological Records* 15: 24-33. <https://doi.org/10.47278/journal.abr/2023.045>
- Menichetti F, Berteotti C, Schirinzi V, Poli C, Arrighi R, Leone A. (2025). *Moringa oleifera* and blood pressure: Evidence and potential mechanisms. *Nutrients* 17(7): 1258. <https://doi.org/10.3390/nu17071258>
- Mohammed GM, Hawar SN. (2022). Green biosynthesis of silver nanoparticles from *Moringa oleifera* leaves and its antimicrobial and cytotoxicity activities. *International Journal of Biomaterials* 2022(1): 4136641. <https://doi.org/10.1155/2022/4136641>
- Munir M, Khan I, Almutairi NS, Almutairi AH, Khan B, Mehboob N. (2025). Effect of *Moringa* leaves powder on body weight, glycemic status, lipid profile, and blood pressure in overweight individuals with hyperlipidemia. *Italian Journal of Food Science* 37(1): 210-219. <https://doi.org/10.15586/ijfs.v37i1.2744>
- Murakami K, Rancilio N. (2025). Role of radiotherapy in canine apocrine gland anal sac adenocarcinoma: A review. *Veterinary Oncology* 2(1): 12. <https://doi.org/10.1186/s44356-025-00028-1>
- Nabi K, Le A. (2021). The intratumoral heterogeneity of cancer metabolism. In *The Heterogeneity of Cancer Metabolism*. Cham: Springer International Publishing. pp. 149-160. https://doi.org/10.1007/978-3-030-67212-6_8
- Negoescu A, Borfalău CD, Gal C, Taulescu M, Cătoi C. (2025). Epidemiology of gastrointestinal proliferative neoplastic-like lesions and tumors in dogs and cats: A retrospective study in two Romanian reference laboratories. *Cluj Veterinary Journal* 30(1): 1-8. <https://doi.org/10.52331/cvj.v30i1.91>
- Nelson VK, Sahoo NK, Sahu M, Sudhan HH, Pullaiah CP, Muralikrishna KS. (2020). In vitro anticancer activity of *Eclipta alba* whole plant extract on colon cancer cell HCT-116. *BMC complementary medicine and therapies* 20: 1-8. <https://doi.org/10.1186/s12907-020-0860-9>
- Pappas IS, Siomou S, Bozinou E, Lalas SI. (2021). *Moringa oleifera* leaves crude aqueous extract down-regulates of BRCA1, mta-1 and oncogenes c-myc and p53 in AsPC-1, MCF-7 and HTC-116 cells. *Food Bioscience* 43: 101221. <https://doi.org/10.1016/j.fbio.2021.101221>
- Perumalsamy H, Balusamy SR, Sukweenadhi J, Nag S, MubarakAli D, El-Agamy Farh M, Rahimi S. (2024). A comprehensive review on *Moringa oleifera* nanoparticles: importance of polyphenols in nanoparticle synthesis, nanoparticle efficacy and their applications. *Journal of Nanobiotechnology* 22(1): 71. <https://doi.org/10.1186/s12951-024-1305-8>
- Phannasil P, Roytrakul S, Phaonakrop N, Kupradinun P, Budda S, Butryee C, Tuntipipat S. (2020). Protein expression profiles that underpin the preventive and therapeutic potential of *Moringa oleifera* Lam against azoxymethane and dextran sodium sulfate-induced mouse colon carcinogenesis. *Oncology Letters* 20(2): 1792-1802. <https://doi.org/10.3892/ol.2020.11730>
- Pouya FD, Salehi R, Rasmi Y, Kheradmand F, Fathi-Azarbayjani A. (2023). Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers. *Life Sciences* 332: 122083. <https://doi.org/10.1016/j.lfs.2023.122083>
- Ranasinghe R, Mathai ML, Zulli A. (2022). Cisplatin for cancer therapy and overcoming chemoresistance. *Heliyon* 8(9). <https://doi.org/10.1016/j.heliyon.2022.e09794>
- Reda F, Borjac J, Usta J. (2020). *Moringa oleifera* leaves aqueous extract induce apoptosis in HT29 cell line. *BAU Journal-Science and Technology* 2(1): 7. <https://doi.org/10.31215/baujst.730733>
- Rojas-Armas JP, Palomino-Pacheco M, Arroyo-Acevedo JL, Ortiz-Sánchez JM, Justil-Guerrero HJ, Martínez-Heredia JT, Guzmán Duxtan AJ. (2024). Phytochemical profiling by UHPLC–Q-TOF/MS and chemopreventive effect of aqueous extract of *Moringa oleifera* leaves and benzyl isothiocyanate on murine mammary carcinogenesis. *Molecules* 29(6): 1380. <https://doi.org/10.3390/molecules29061380>
- Rottenberg S, Disler C, Perego P. (2021). The rediscovery of platinum-based cancer therapy. *Nature Reviews Cancer* 21(1): 37-50. <https://doi.org/10.1038/s41568-020-00313-2>
- Sahoo N, Bishi DK, Srivastava V, Pattanayak C, Sarkar S. (2024). Hypolipidemic and hepatoprotective effect of *Linum usitatissimum* and *Moringa oleifera* seeds in diabetic induced damage in rats. *Journal of Pharmacology and Pharmacotherapeutics*, 0976500X241303668. <https://doi.org/10.1177/0976500X241303668>
- Samrot AV, Ram Singh SP, Deenadhayalan R, Rajesh VV, Padmanaban S, Radhakrishnan K. (2022). Nanoparticles, a double-edged sword with oxidant as well as antioxidant properties—a review. *Oxygen* 2(4): 591-604. <https://doi.org/10.3390/oxygen2040046>
- Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Marra MA. (2018). Oncogenic signaling pathways in the cancer genome atlas. *Cell* 173(2): 321-337. <https://doi.org/10.1016/j.cell.2018.03.055>
- Saradha S, Abitha R, Prasath KH, Logithkumar S, Vijayashree R, Devi TS. (2024). Assessment of anticancer activity of crude ethanolic extracts of *Moringa oleifera* pod and leaves on 7, 12-

- dimethylbenz[a]anthracene-induced skin cancer in mice. *Biomedical and Pharmacology Journal* 17(1): 243–251. <https://doi.org/10.13005/bpj/2725>
- Sarani M, Roostae M, Adeli-Sardou M, Kalantar-Neyestanaki D, Mousavi SAA, Amanizadeh A, Amirbeigi A. (2024). Green synthesis of Ag and Cu-doped Bismuth oxide nanoparticles: revealing synergistic antimicrobial and selective cytotoxic potentials for biomedical advancements. *Journal of Trace Elements in Medicine and Biology* 81: 127325. <https://doi.org/10.1016/j.jtemb.2023.127325>
- Sati A, Ranade TN, Mali SN, Ahmad Yasin HK, Pratap A. (2025). Silver nanoparticles (agNPs): comprehensive insights into bio/synthesis, key influencing factors, multifaceted applications, and toxicity—a 2024 update. *ACS Omega* 10(8): 7549–7582. <https://doi.org/10.1021/acsomega.4c11045>
- Saurav S, Karfa S, Vu T, Liu Z, Datta A, Manne U, Datta PK. (2024). Overcoming irinotecan resistance by targeting its downstream signaling pathways in colon cancer. *Cancers* 16(20): 3491. <https://doi.org/10.3390/cancers16204022>
- Sayed HM, Said MM, Morcos NY, El Gawish MA, Ismail AF. (2021). Antitumor and radiosensitizing effects of zinc oxide-cafeic acid nanoparticles against solid ehrlich carcinoma in female mice. *Integrative Cancer Therapies* 20: 15347354211021920. <https://doi.org/10.1177/15347354211021920>
- Shafiq A, Aftab M, Nadeem A, Rasheed MS, Awan I, Khalil MT, Ali MM, Saeed HA, Zafar MZ. (2024). Impact of *Fusobacterium nucleatum* infection on ferroptosis suppression, oxidative stress, and prognostic outcomes in esophageal squamous cell carcinoma. *Agrobiological Records* 18: 96–104. <https://doi.org/10.47278/journal.abr/2024.041>
- Shahbaz M, Naeem H, Batool M, Imran M, Hussain M, Mujtaba A, Al Jbawi E. (2024). Antioxidant, anticancer, and anti-inflammatory potential of Moringa seed and Moringa seed oil: A comprehensive approach. *Food Science & Nutrition* 12(9): 6157–6173. <https://doi.org/10.1002/fsn3.4312>
- Shekarabi D, Safi S, Mortazavi P. (2025). Evaluation of apoptosis and caspase-3 activity in EL4 cell line lymphoma using *Moringa oleifera* plant extract. *Archives of Razi Institute* 80(1): 37–50. <https://doi.org/10.32592/ARI.2025.80.1.37>
- Shousha WG, Aboulthana WM, Salama AH, Saleh MH, Essawy EA. (2019). Evaluation of the biological activity of *Moringa oleifera* leaves extract after incorporating silver nanoparticles, in vitro study. *Bulletin of the National Research Centre* 43(1): 1–13. <https://doi.org/10.1186/s42269-019-0221-8>
- Sodvadiya M, Patel H, Mishra A, Nair S. (2020). Emerging insights into anticancer chemopreventive activities of nutraceutical *Moringa oleifera*: Molecular mechanisms, signal transduction and in vivo efficacy. *Current Pharmacology Reports* 6: 38–51. <https://doi.org/10.1007/s40495-020-00159-2>
- Song Q, Wu H, Jin Y, Hou J, Liu J, Zhang X, Zhang Z. (2025). Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF- β /Smad signaling pathway. *Frontiers in Oncology* 15: 1503133. <https://doi.org/10.3389/fonc.2025.1503133>
- Suardana IW, Wihadmadyatami H, Widiastih DA. (2024). Anticancer activity of the 28.4 kDa protein from *Pediococcus pentosaceus* SR6 in MCF-7 breast cancer cell line. *International Journal of Veterinary Science* 13(6): 742–748. <https://doi.org/10.47278/journal.ijvs/2024.158>
- Sun X, Meng Y, Hu K, Sun J, Zhou C, Su C, Ma Z. (2024). Crystallization-driven formation of cluster assemblies on surface for super-hydrophobic poly (L-lactic acid)/ZnO composite membrane. *International Journal of Biological Macromolecules* 283: 137815. <https://doi.org/10.1016/j.jbiomac.2024.137815>
- Suryanarayana C, Al-Joubori AA, Wang Z. (2022). Nanostructured materials and nanocomposites by mechanical alloying: an overview. *Metals and Materials International* 28(1): 41–53. <https://doi.org/10.1007/s12540-021-00024-3>
- Susanto H, Firdaus SDRA, Sholeh M, Endharti AT, Taufiq A, Malek NANN, Permatasari HK. (2024). *Moringa oleifera* leaf powder–silver nanoparticles (MOLP-AgNPs) efficiently inhibit metastasis and proliferative signaling in HT-29 human colorectal cancer cells. *Journal of Agriculture and Food Research* 16: 101149. <https://doi.org/10.1016/j.jafr.2023.101149>
- Syaj S, Saeed A. (2024). Profile of Fruquintinib in the Management of Advanced Refractory Metastatic Colorectal Cancer: Design, Development and Potential Place in Therapy. *Drug Design, Development and Therapy* 15: 5203–5210. <https://doi.org/10.2147/DDDT.S48993>
- Szlachetka K, Kut P, Stepień A. (2020). Cytotoxic and anticancer activity of *Moringa oleifera*. In: *Cytotoxic and Anticancer Activities of Plant-Derived Compounds* pp. 117–136. <https://doi.org/10.1201/9781003083267-7>
- Taieb J, Aranda E, Raouf S, Dunn H, Arnold D. (2021). Clinical and regulatory considerations for the use of bevacizumab biosimilars in metastatic colorectal cancer. *Clinical Colorectal Cancer* 20(1): 42–51. <https://doi.org/10.1016/j.clcc.2021.02.001>
- Tan G, Lin C, Huang C, Chen B, Chen J, Shi Y, Zhi F. (2022). Radiosensitivity of colorectal cancer and radiation-induced gut damages are regulated by gasdermin E. *Cancer Letters* 529: 1–10. <https://doi.org/10.1016/j.canlet.2021.11.028>
- Tragulpakseerojn J, Yamaguchi N, Pamonsinlapatham P, Wetwitayaklung P, Yoneyama T, Ishikawa N, Apirakaramwong A. (2017). Anti-proliferative effect of *Moringa oleifera* Lam (Moringaceae) leaf extract on human colon cancer HCT116 cell line. *Tropical Journal of Pharmaceutical Research* 16(2): 371–378. <https://doi.org/10.4314/tjpr.v16i2.20>
- Váradí C, Jakes C, Bones J. (2020). Analysis of cetuximab N-Glycosylation using multiple fractionation methods and capillary electrophoresis mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis* 180: 113035. <https://doi.org/10.1016/j.jpba.2019.113035>
- Venkatadri B, Shanparvish E, Rameshkumar MR, Arasu MV, Al-Dhabi NA, Ponnusamy VK, Agastian P. (2020). Green synthesis of silver nanoparticles using aqueous rhizome extract of *Zingiber officinale* and *Curcuma longa*: in-vitro anti-cancer potential on human colon carcinoma HT-29 cells. *Saudi Journal of Biological Sciences* 27(11): 2980–2986. <https://doi.org/10.1016/j.sjbs.2020.09.021>
- Vidaarth TN, Surendhiran S, Jagan KSG, Savitha S, Balu KS, Karthik A, Kalpana B. (2024). Surface chemistry of phytochemical enriched MgO nanoparticles for antibacterial, antioxidant, and textile dye degradation applications. *Journal of Photochemistry and Photobiology A: Chemistry* 448: 115349. <https://doi.org/10.1016/j.jphotochem.2023.115349>
- Vijayakumar S, Chen J, Sánchez ZIG, Tungare K, Bhoori M, Durán-Lara EF, Anbu P. (2023). *Moringa oleifera* gum capped MgO nanoparticles: Synthesis, characterization, cyto-and ecotoxicity assessment. *International Journal of Biological Macromolecules*

- 233: 123514. <https://doi.org/10.1016/j.ijbiomac.2023.123514>
- Virk P, Alrowaily AW, Bahloul T, Al-Abbas F, Aouaini F, Ortashi KMO. (2023). Synthesis of Nano-Crystalline Whiskers of Cheese and Their Efficacy against Cadmium Toxicity. *Crystals* 2023, 13: 1013. <https://doi.org/10.3390/cryst13050756>
- Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. (2020). 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. *Pharmacology & therapeutics* 206: 107447. <https://doi.org/10.1016/j.pharmthera.2020.107447>
- Waliaveettil FA, Anila EI. (2024). A Comprehensive Review on Antibacterial, Anti-Inflammatory and Analgesic Properties of Noble Metal Nanoparticles. *Particle & Particle Systems Characterization* 41(5): 2300162. <https://doi.org/10.1002/ppsc.202300162>
- Wang J. (2019). Proliferative and invasive colorectal tumors in pet dogs provide unique insights into human colorectal cancer. PhD Thesis, University of Guelph. <https://hdl.handle.net/10214/16055>
- Wong MC, Huang J, Lok V, Wang J, Fung F, Ding H, Zheng ZJ. (2021). Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location. *Clinical Gastroenterology and Hepatology* 19(5): 955-966. <https://doi.org/10.1016/j.cgh.2020.07.006>
- Wu Y, Jia H, Bao X, Zhu T, Li R, Zhao H, Sun J. (2020). Gastrointestinal disasters of cetuximab in the treatment of metastatic colorectal cancer: Mechanism and its effect on prognosis. *Aging Pathobiology and Therapeutics* 2(2): 64-72. <https://doi.org/10.20900/aph.20200017>
- Xiao JB, Leng AM, Zhang YQ, Wen Z, He J, Ye GN. (2019). CUEDC2: multifunctional roles in carcinogenesis. *Front Biosci (Landmark Ed)* 24(5): 935-946. <https://doi.org/10.2741/8775>
- Xie Q, Liu Y, Li X. (2020). The interaction mechanism between autophagy and apoptosis in colon cancer. *Translational Oncology* 13(12): 100871. <https://doi.org/10.1016/j.tranon.2020.100871>
- Xie R, Ponnampalam EN, Ahmadi F, Dunshea FR, Suleria HA. (2024). Antioxidant potential and characterization of polyphenol compounds in *Moringa oleifera* pods. *Food Science & Nutrition* 12(12): 10881-10902. <https://doi.org/10.1002/fsn3.4628>
- Yenurkar D, Choudhary A, Shrivastava A, Pragya P, Mandal S, Soni P, Mukherjee S. (2025). Potassium ferric oxalate nanoparticles prevent human blood clotting and thrombosis in a mouse model. *ACS Applied Materials & Interfaces* 17(19): 28395–28410 <https://doi.org/10.1021/acsami.5c04112>
- You XH, Jiang YH, Fang Z, Sun F, Li Y, Wang W, Ying HQ. (2020). Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. *ESMO Open* 5(2): e000605. <https://doi.org/10.1136/esmoopen-2019-000605>
- Zhao M, Xu J, Ye W, Gui Y, Zhao J, Qiao Y, Yan Y. (2024). Microstructure and tensile properties of Y2O3-dispersion strengthened CoCrFeNi high entropy alloys prepared via mechanical alloying using pre-alloyed powder. *Journal of Materials Research and Technology* 33: 349-360. <https://doi.org/10.1016/j.jmrt.2024.09.061>
- Žok J, Bieńkowski M, Radecka B, Korniluk J, Adamowicz K, Duchnowska R. (2021). Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study. *BMC Cancer* 21: 1-10. <https://doi.org/10.1186/s12885-021-08720-7>

Citation

Haider H, Kausar I, Parvaiz M, Riffat H, Shahbaz MA, Hussain N, Pari N, Khudhair OD, Zabidi MA, Shehzad T. (2025). Exploring anticancer properties of Moringa and its derived by-products against colon cancer in humans and animals. *Letters in Animal Biology* 05(2): 95 – 106. <https://doi.org/10.62310/liab.v5i2.233>